Leerink Partnrs Issues Positive Estimate for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for Neurocrine Biosciences in a research note issued to investors on Monday, February 17th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $0.77 per share for the quarter, up from their prior forecast of $0.70. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences' Q2 2025 earnings at $1.18 EPS, FY2027 earnings at $8.85 EPS and FY2029 earnings at $9.00 EPS.

Other analysts have also recently issued research reports about the stock. Royal Bank of Canada cut their target price on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating for the company in a research note on Friday, February 7th. Bank of America dropped their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Barclays upped their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a research note on Monday, December 23rd. Wedbush dropped their price objective on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Finally, Guggenheim dropped their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a research note on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and an average price target of $166.90.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock traded up $4.58 on Thursday, reaching $120.69. 1,960,426 shares of the company were exchanged, compared to its average volume of 1,340,165. The company has a market cap of $12.03 billion, a price-to-earnings ratio of 36.68, a P/E/G ratio of 0.76 and a beta of 0.33. The business has a 50-day moving average price of $136.75 and a 200 day moving average price of $129.71. Neurocrine Biosciences has a 1 year low of $110.95 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Institutional Investors Weigh In On Neurocrine Biosciences

Large investors have recently added to or reduced their stakes in the business. Golden State Wealth Management LLC purchased a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $25,000. Huntington National Bank increased its position in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares during the last quarter. GeoWealth Management LLC increased its position in shares of Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after purchasing an additional 102 shares during the last quarter. Finally, Blue Trust Inc. increased its position in shares of Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 65,000 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the sale, the chief executive officer now directly owns 135,392 shares of the company's stock, valued at $19,157,968. This represents a 32.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 236,600 shares of company stock worth $34,348,261. 4.30% of the stock is currently owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.